Oregon wrestles with offering psychedelics outside medical system; follow-up care for depression falls short

The psychedelic legalization movement is progressing parallel to a gold rush to develop these same drugs as medicine. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

'It's not medical': Oregon wrestles with how to offer psychedelics outside the health care system By Olivia Goldhill Ayşe Gürsöz for STAT The psychedelic legalization movement is progressing parallel to a gold rush to develop these same drugs as medicine. Read More Widespread screening catches more cases of depression. But follow-up care still falls far short By Tino Delamerced Adobe New research finds that timely follow-up care is often lacking after a patient screens positive for depression. Read More Opinion: Gaslighting of Black medical trainees makes residency something to 'survive' By Shenelle Wilson Adobe Judged by racially biased metrics and subject to gaslighting, Black medical trainees represent 20% of all residents dismissed from training. Read More Sponsor content by STAT Events The STAT Breakthrough Science Summit On March 31, take an inside look at the technologies and procedures set to redefine medicine, and change patient care in the years to come. You'll hear from the CEOs, scientists, entrepreneurs at the forefront of these efforts. Get your pass now, and use your STAT+ subscriber login to unlock a 20% discount. As providers are accused of interfering with access to patient data, pressure builds on government to act By Mohana Ravindranath Adobe Health tech leaders and former federal officials are calling for a more aggressive approach to instances of "information blocking." Read More Listen: Gilead's growing pains, Covid's origins, & Theranos as prestige TV By Damian Garde and Meg Tirrell and Adam Feuerstein This week, we examine Gilead Sciences' recent struggles and what the company's predicament says about the drug industry. Read More 'Scum of the earth': Opioid crisis victims face Purdue Pharma owners By Geoff Mulvihill and Jennifer Peltz — Associated Press Josh Reynolds/AP The hearing gave victims and survivors the chance to confront members of the Sackler family who own OxyContin maker Purdue Pharma. Read More New research casts doubt on a cornerstone of thyroid cancer treatment By Angus Chen Adobe Emerging research casts doubt on whether radiation therapy after surgery actually benefits patients with certain thyroid cancers. Read More Thursday, March 10, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser